Aflibercept for treatment-naive diabetic macula oedema in a multi-ethnic population: Real-world outcomes from North West London.

ABSTRACT:

Purpose

To evaluate the clinical outcomes of patients with treatment-naïve diabetic macula oedema (DMO) treated with Aflibercept in routine clinic settings in ethnically diverse North West London (NWL) and compare to outcomes reported in the VIVID and VISTA clinical trials.

Methods

This was a retrospective multicentre interventional case series. Two hundred and seventy eyes of 221 treatment-naïve patients at three NWL hospitals initiated on Aflibercept and who had at least 12 months follow-up were included in the study. Visual acuity, central subfield thickness and macula volume were recorded at baseline, month 3, 6 and 12.

Results

There were significant differences between the NWL cohort and participants in the VIVID and VISTA trials at baseline including higher HbA1

SUBMITTER: Dinah C 

PROVIDER: S-EPMC7877641 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature